Corcept Therapeutics Inc (CORT)
32.49
+0.43
(+1.34%)
USD |
NASDAQ |
Jun 28, 16:00
32.50
+0.01
(+0.03%)
After-Hours: 20:00
Corcept Therapeutics Research and Development Expense (Annual): 184.35M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 184.35M |
| December 31, 2022 | 130.99M |
| December 31, 2021 | 113.86M |
| December 31, 2020 | 114.76M |
| December 31, 2019 | 89.02M |
| December 31, 2018 | 75.25M |
| December 31, 2017 | 40.38M |
| December 31, 2016 | 23.84M |
| December 31, 2015 | 15.42M |
| December 31, 2014 | 18.37M |
| December 31, 2013 | 20.47M |
| December 31, 2012 | 14.07M |
| Date | Value |
|---|---|
| December 31, 2011 | 21.00M |
| December 31, 2010 | 18.95M |
| December 31, 2009 | 14.40M |
| December 31, 2008 | 14.15M |
| December 31, 2007 | 7.86M |
| December 31, 2006 | 20.83M |
| December 31, 2005 | 17.07M |
| December 31, 2004 | 11.55M |
| December 31, 2003 | 8.223M |
| December 31, 2002 | 13.26M |
| December 31, 2001 | 5.39M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
89.02M
Minimum
2019
184.35M
Maximum
2023
126.60M
Average
114.76M
Median
2020
Research and Development Expense (Annual) Benchmarks
| Regeneron Pharmaceuticals Inc | 4.439B |
| Ligand Pharmaceuticals Inc | 24.54M |
| Warby Parker Inc | -- |
| NovaBay Pharmaceuticals Inc | 0.068M |
| Palatin Technologies Inc | 22.63M |